ChemicalBook >> journal list >> Theranostics >>article
Theranostics

Theranostics

IF: 13.3
Download PDF

Reprogramming Exosomes to Escape from Immune Surveillance for Mitochondrial Protection in Hepatic Ischemia-Reperfusion Injury

Published:1 January 2024 DOI: 10.7150/thno.88061 PMID: 38164154
Shanshan Liu, Xinyu Xiao, La Zhang, Jianwei Wang, Wei Zhao, Haichuan Liu, Rui Liao, Zhi Li, Mengxia Xu, Jiao Guo, Baoyong Zhou, Chengyou Du, Qiling Peng, Ning Jiang

Abstract

Background: Therapeutic interventions such as synthetic drugs and microRNA (miR) modulators have created opportunities for mitigating hepatic ischemia/reperfusion injury (HIRI) by alleviating mitochondrial dysfunction. However, delivering multi-therapeutic ingredients with low toxicity to hepatocytes still lags behind its development. Methods: In this study, we endowed exosomes with delivery function to concentrate on hepatocytes for multidimensionally halting mitochondria dysfunction during HIRI. Concretely, exosomes were reprogrammed with a transmembrane protein CD47, which acted as a "camouflage cloak" to mimic the "don't eat me" mechanism to escape from immune surveillance. Besides, HuR was engineered bridging to the membrane by fusing with CD47 and located in the cytoplasm for miR loading. Results: This strategy successfully delivered dual payloads to hepatocytes and efficiently protected mitochondria by inhibiting the opening of mitochondrial permeability transition pore (mPTP) and upregulating mitochondrial transcription factor A (TFAM), respectively. Conclusions: The reprogramming of exosomes with CD47 and HuR for targeted delivery of CsA and miR inhibitors represents a promising therapeutic strategy for addressing HIRI. This approach shows potential for safe and effective clinical applications in the treatment of HIRI.

Similar articles

IF:3

Neuroprotective effects of phenylacetylglycine via β2AR on cerebral ischemia/reperfusion injury in rats

Saudi Pharmaceutical Journal Wenjie Hu, Xueyan Kuang,etc Published: 1 December 2024
IF:4.3

Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

ACS Applied Electronic Materials Christopher J De Feo, Carol D Weiss,etc Published: 1 December 2012